Velan Capital Investment Management LP
Reported holdings as of Q2 2026, from 19 quarterly filings.
Holdings
| Security | Ticker | Value | Shares | Weight | Weight change | Held | Change |
|---|---|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES I | PRAX | $29.7M | 88,781 | -2.24pp | 11q | -11.9%-$4.0M | |
| MAPLIGHT THERAPEUTICS INC | MPLT | $17.7M | 492,893 | +4.48pp | 3q | HELD | |
| SUTRO BIOPHARMA INC | STRO | $17.0M | 512,160 | +2.36pp | 3q | HELD | |
| IMMIX BIOPHARMA INC | IMMX | $11.2M | 1,085,000 | +2.59pp | 5q | +46.6%+$3.6M | |
| PROTARA THERAPEUTICS INC | TARA | $10.9M | 2,844,652 | -2.63pp | 9q | HELD | |
| TENAX THERAPEUTICS INC OPT | TENX | $9.0M | 549,985 | -0.36pp | 8q | -5.7%-$545.8K | |
| ABIVAX SA | ABVX | $8.7M | 65,630 | -0.04pp | 4q | -14.8%-$1.5M | |
| ANTERIS TECHNOLOGIES GLOBAL | AVR | $6.9M | 700,000 | +1.77pp | 2q | HELD | |
| EDESA BIOTECH INC | EDSA | $6.7M | 827,500 | +1.39pp | 6q | HELD | |
| EVOMMUNE INC | EVMN | $6.0M | 451,255 | -2.77pp | 3q | +1.1%+$66.5K | |
| AVALO THERAPEUTICS INC | AVTX | $6.0M | 324,452 | +1.92pp | 7q | +75.3%+$2.6M | |
| XENCOR INC | XNCR | $4.1M | 255,000 | +0.61pp | 2q | +2.0%+$80.5K | |
| REZOLUTE INC | RZLT | $3.9M | 750,000 | +0.94pp | 10q | HELD | |
| HERON THERAPEUTICS INC | HRTX | $3.7M | 8,753,290 | -2.11pp | 15q | HELD | |
| VERRICA PHARMACEUTICALS INC | VRCA | $2.9M | 471,559 | +0.19pp | 3q | HELD | |
| C4 THERAPEUTICS INC | CCCC | $2.7M | 570,000 | - | new | NEW | |
| EUPRAXIA PHARMACEUTICALS INC | EPRX | $2.3M | 352,000 | -0.18pp | 4q | HELD | |
| ADMA BIOLOGICS INC | ADMA | $2.1M | 250,000 | - | new | NEW | |
| REIN THERAPEUTICS INC | RNTX | $1.8M | 1,700,000 | - | new | NEW | |
| LYELL IMMUNOPHARMA INC | LYEL | $1.5M | 105,000 | -0.38pp | 2q | +2.9%+$42.1K | |
| NASUS PHARMA LTD | NSRX | $1.3M | 359,390 | +0.27pp | 2q | HELD | |
| PROFOUND MED CORP | PROF | $1.1M | 170,278 | -0.47pp | 3q | -40.4%-$767.6K | |
| JASPER THERAPEUTICS INC | JSPR | $1.1M | 2,668,395 | -0.78pp | 10q | HELD | |
| PROTAGONIST THERAPEUTICS INC | PTGX | $453.5K | 3,700 | +0.03pp | 5q | HELD | |
| CYTOMX THERAPEUTICS INC | CTMX | $450.0K | 120,000 | -1.32pp | 7q | -77.8%-$1.6M | |
| NEUMORA THERAPEUTICS INC. | NMRA | $391.0K | 230,000 | +0.14pp | 2q | +187.5%+$255.0K | |
| NURIX THERAPEUTICS INC | NRIX | $388.2K | 16,000 | +0.08pp | 5q | HELD | |
| OVID THERAPEUTICS INC | OVID | $349.7K | 130,000 | -0.01pp | 7q | -18.8%-$80.7K | |
| PRECISION BIOSCIENCES INC | DTIL | $314.4K | 40,000 | +0.05pp | 4q | HELD | |
| MINERALYS THERAPEUTICS INC | MLYS | $296.8K | 11,000 | -0.01pp | 6q | HELD | |
| MACROGENICS INC | MGNX | $277.2K | 60,000 | +0.11pp | 2q | +100.0%+$138.6K | |
| CORBUS PHARMACEUTICALS HLDGS | CRBP | $243.9K | 26,000 | flat | 8q | HELD | |
| ARTIVA BIOTHERAPEUTICS INC | ARTV | $242.5K | 25,000 | +0.05pp | 2q | HELD | |
| REPLIMUNE GROUP INC | REPL | $221.4K | 20,000 | +0.04pp | 7q | HELD | |
| SYNDAX PHARMACEUTICALS INC | SNDX | $218.6K | 10,000 | -0.01pp | 4q | HELD | |
| IMMUNOME INC | IMNM | $211.9K | 10,000 | -0.01pp | 4q | HELD | |
| TECTONIC THERAPEUTIC INC | TECX | $206.2K | 6,000 | - | new | NEW | |
| ROCKET PHARMACEUTICALS INC | RCKT | $205.2K | 60,000 | -0.54pp | 2q | -79.6%-$802.5K | |
| KARYOPHARM THERAPEUTICS INC | KPTI | $195.4K | 20,000 | +0.07pp | 2q | +33.3%+$48.9K | |
| AN2 THERAPEUTICS INC | ANTX | $193.6K | 40,000 | - | new | NEW | |
| VIRIDIAN THERAPEUTICS INC | VRDN | $183.7K | 10,000 | -1.00pp | 5q | -89.0%-$1.5M | |
| SCYNEXIS INC | $162.8K | 40,000 | - | new | NEW | ||
| QUOIN PHARMACEUTICALS LTD | QNRX | $156.7K | 32,372 | -0.26pp | 2q | -61.8%-$254.0K | |
| XILIO THERAPEUTICS INC | XLO | $136.8K | 14,285 | +0.01pp | 2q | HELD | |
| INSPIREMD INC | NSPR | $103.7K | 148,138 | -2.08pp | 13q | -92.9%-$1.4M | |
| KALARIS THERAPEUTICS INC | KLRS | $101.8K | 25,000 | flat | 2q | +38.9%+$28.5K | |
| LARIMAR THERAPEUTICS INC | LRMR | $100.7K | 33,000 | -0.03pp | 7q | HELD | |
| PROQR THRAPEUTICS N V | PRQR | $83.7K | 45,000 | +0.01pp | 7q | HELD | |
| CONTEXT THERAPEUTICS INC | CNTX | $33.1K | 59,700 | -0.14pp | 9q | -40.3%-$22.3K | |
| GOSSAMER BIO INC | GOSS | $11.5K | 70,000 | -0.01pp | 7q | HELD |
By sector
Industry comes from the SIC code on each company's own SEC filings, which is self-reported and sometimes out of date. Derivative exposure is counted with the shares. Securities the SEC assigns no industry - funds, trusts, foreign issues - are shown as not classified rather than dropped.
| Sector | Value | Share |
|---|---|---|
| Biotech & Pharma | $155.9M | 94.9% |
| Medical Devices | $8.1M | 5.0% |
| Not classified | $162.8K | 0.1% |
Quarter by quarter
| Quarter | Value | Positions | New | Added | Trimmed | Exited | Top 10 | Days to file |
|---|---|---|---|---|---|---|---|---|
| Q2 2026 | $164.2M | 50 | 6 | 9 | 11 | 5 | 75.4% | 45 |
| Q1 2026 | $159.6M | 49 | 12 | 12 | 7 | 9 | 73.1% | 45 |
| Q4 2025 | $172.4M | 46 | 9 | 5 | 5 | 12 | 71.0% | 44 |
| Q3 2025 | $106.5M | 49 | 11 | 14 | 5 | 12 | 68.2% | 45 |
| Q2 2025 | $101.2M | 50 | 10 | 16 | 5 | 7 | 69.3% | 45 |
| Q1 2025 | $97.2M | 47 | 10 | 16 | 2 | 8 | 76.7% | 45 |
| Q4 2024 | $115.9M | 45 | 32 | 4 | 2 | 5 | 86.6% | 45 |
| Q3 2024 | $106.9M | 18 | 6 | 2 | 3 | 5 | 92.2% | 45 |
| Q2 2024 | $174.6M | 17 | 5 | 2 | 2 | 9 | 95.5% | 45 |
| Q1 2024 | $220.2M | 21 | 8 | 2 | 3 | 7 | 90.3% | 44 |
| Q4 2023 | $171.3M | 20 | 7 | 3 | 1 | 15 | 88.2% | 45 |
| Q3 2023 | $124.0M | 28 | 4 | 4 | 5 | 6 | 78.2% | 44 |
| Q2 2023 | $107.7M | 30 | 7 | 9 | 4 | 8 | 66.2% | 42 |
| Q1 2023 | $117.3M | 31 | 14 | 5 | 2 | 11 | 77.5% | 45 |
| Q4 2022 | $113.2M | 28 | 12 | 3 | 4 | 8 | 80.0% | 44 |
| Q3 2022 | $100.8M | 24 | 7 | 6 | 4 | 6 | 84.9% | 45 |
| Q2 2022 | $98.6M | 23 | 6 | 6 | 3 | 6 | 86.9% | 46 |
| Q1 2022 | $107.8M | 23 | 4 | 4 | 3 | 8 | 79.9% | 46 |
| Q4 2021 | $128.9M | 27 | 0 | 0 | 0 | 0 | 77.3% | 45 |
Rows marked UNVERIFIED ID, PLACEHOLDER ID, TICKER AS ID or NON-CUSIP ID carry an identifier that is not a valid CUSIP. They are shown because the filer reported that money, but treat the security named with caution - hover the chip for what is wrong with it, and see the methodology.
Held counts consecutive filings in which this manager reported the position, and can reach further back than the quarters listed above: the tabs begin at Q4 2018 because earlier coverage is too sparse to describe a market, but tenure is counted over every filing we hold, some reaching to 2007. A position sold and later rebought starts again from one.
Weight change is the shift in this position's share of the whole book, in percentage points. It is the more useful column: when money flows into or out of a broad fund, almost every holding is bought or sold at once, so added and trimmed largely track flows. A weight that rose while the book shrank is a decision. Both compare with the previous quarter this filer reported, not the previous calendar quarter.